Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer

被引：2

作者：

Chang, Jenny C. ^{[1
]}

O'Regan, Ruth ^{[2
,3
,4
]}

机构：

[1] Houston Methodist Canc Ctr, Houston, TX 77030 USA

[2] Univ Wisconsin, Sch Med & Publ Hlth, Med, Madison, WI 53706 USA

[3] Carbone Canc Ctr, Hematololgy Oncol Div, Madison, WI USA

[4] Carbone Canc Ctr, Clin Res, Madison, WI USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷

关键词：

METASTATIC BREAST-CANCER; 4/6 INHIBITOR PALBOCICLIB; RANDOMIZED PHASE-II; FULVESTRANT; 500; MG; ANASTROZOLE; ENDOCRINE THERAPY; DOUBLE-BLIND; AROMATASE INHIBITORS; ESR1; MUTATIONS; 1ST-LINE TREATMENT;

D O I：

10.6004/jnccn.2018.0200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy remains the backbone for treatment of hormone receptor-positive breast cancer in the metastatic setting. Despite the effectiveness of endocrine therapy, primary and acquired endocrine resistance continue to be important clinical challenges. The landscape of metastatic breast cancer treatment has changed considerably with the incorporation of novel agents, including cyclin-dependent kinase 4/6 and mammalian target of rapamycin inhibitors. This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer.

引用

页码：S1 / S14

页数：14

共 50 条

[1] SG Improves OS in HR+/HER2-Breast Cancer
Poh, Alissa
CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
[2] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2-BREAST CANCER IN ARGENTINA
Novick, D.
Moneta, M., V
Fischman, M.
Zarino, N.
Gallino, J.
Carter, Cuyun G.
Haro, J. M.
VALUE IN HEALTH, 2020, 23 : S62 - S63
[3] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
Sarina, Piha-Paul
Xu, Binghe
Fan, Ying
Yuan, Yuan
Lavasani, Sayeh
Mortimer, Joanne
Goel, Sanjay
Tsimberidou, Apostolia
Ibrahim, Nuhad
Abouharb, Sausan
Barcenas, Carlos
Lheme, Adaeze
Karp, Daniel
Ahnert, Jordi Rodon
Dumbrava, Ecaterina
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Xu, Ruolan
Ni, Shumao
Wu, Frank
Meric-Bernstam, Funda
CANCER RESEARCH, 2024, 84 (09)
[4] Everolimus and Exemestane An Innovative Therapeutic Option for Patients with advanced HR+, HER2-Breast Cancer
Grischke, Eva-Maria
Geberth, Matthias
Harbeck, Nadia
AKTUELLE NEUROLOGIE, 2014, 41 (08) : 4 - 6
[5] Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCR
Dey, Nandini
Aske, Jennifer
De, Pradip
CANCERS, 2021, 13 (03) : 1 - 14
[6] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
Mitra, D.
Darden, C.
McSorley, D.
Davis, K.
Band, J.
Iyer, S.
VALUE IN HEALTH, 2018, 21 : S36 - S36
[7] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
Kang, Connie
TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
[8] Comprehensive genomic profiling of advanced HR+/HER2-breast cancer patients using liquid biopsy
Shao, B.
Tang, H.
Liu, X-R.
Song, G.
Di, L.
Xie, F.
Jia, C.
Zhang, Y.
Jia, S.
Li, H.
ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389
[9] Impact of molecular subtype and race on HR+, HER2-breast cancer survival
Reid, Sonya
Haddad, Diane
Tezak, Ann
Weidner, Anne
Wang, Xuefeng
Mautz, Brian
Moore, Jaleesa
Cadiz, Sydney
Zhu, Yuwei
Zheng, Wei
Mayer, Ingrid A.
Shu, Xiao-ou
Pal, Tuya
BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 845 - 852
[10] Tumour stroma characterization for the clinical stratification of HR+/HER2-breast cancer
Scatena, C.
Fanelli, G. N.
Belcastro, E.
Di Cocco, F.
Fontana, A.
Szumera-Cieckiewicz, A.
Loda, M.
Naccarato, A. G.
VIRCHOWS ARCHIV, 2024, 485 : S5 - S5

← 1 2 3 4 5 →